KAKoichi Araki

Koichi Araki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Koichi Araki has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Satomi Ando

    Center for Inflammation and Tolerance, Cincinnati Children’s Hospital Medical Center 1 Division of Infectious Diseases Cincinnati, OH

    3 shared publications
  • Rafi Ahmed

    Emory Vaccine Center, Emory University School of Medicine

    2 shared publications
  • Yamato Sajiki

    Center for Inflammation and Tolerance, Cincinnati Children’s Hospital Medical Center 1 Division of Infectious Diseases Cincinnati, OH

    2 shared publications
  • Amanda L. Gill

    Emory Vaccine Center, Emory University School of Medicine, Atlanta, USA

    1 shared publication
  • Andreas Wieland

    Department of Otolaryngology-Head and Neck Surgery, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center

    1 shared publication
  • Autumn Gavora

    Emory Vaccine Center and Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30329, USA

    1 shared publication

Latest Publications

  • Functional heterogeneity and plasticity in naïve CD8 T cells drive superior effector and memory responses

    by Yamato Sajiki, Satomi Ando, Charles M. Perkins, Yi-Chung Huang, Katie E. Smith, Carolyn M. Doerning, David A. Hildeman, Koichi Araki

    While significant progress has been made in defining subsets among antigen-experienced CD8 T cells, the heterogeneity of naïve CD8 T cells remains poorly understood. Here, we identify naïve CD8 T cell subsets with superior persistence and an enhanced capacity to generate effector and memory cells, leading to more effective protection. These functionally superior naïve CD8 T cells are marked by IL-18Rα, CD73, and CXCR3, and functionally less potent naïve CD8 T cells can convert into these superior subsets through tonic TCR signaling. Their enhanced response to infections is driven by better survival of the progeny effector cells during the T cell expansion phase. This improved survival is mediated by increased Ly6C expression on effector cells derived from these functionally superior naïve cells. Collectively, our findings reveal functional heterogeneity and plasticity among naïve CD8 T cells and uncover a mechanism by which functionally superior naïve subsets drive robust CD8 T cell responses, providing a previously unrecognized layer of immune regulation.


  • Open Access

    Functional heterogeneity and plasticity in naïve CD8 T cells drive superior effector and memory responses

    by Yamato Sajiki, Satomi Ando, Charles M. Perkins, Yi-Chung Huang, Katie E. Smith, Carolyn M. Doerning, Koichi Araki

    While significant progress has been made in defining subsets among antigen-experienced CD8 T cells, the heterogeneity of naïve CD8 T cells remains poorly understood. Here, we identify naïve CD8 T cell subsets with superior persistence and an enhanced capacity to generate effector and memory cells, leading to more effective protection. These high-quality naïve CD8 T cells are marked by IL-18Rα, CD73, and CXCR3, and functionally less potent naïve CD8 T cells can convert into these superior subsets. Their enhanced response to infections is driven by better survival of the progeny effector cells during the T cell expansion phase. This improved survival is mediated by increased Ly6C2 expression on effector cells derived from these high-quality naïve cells. Collectively, our findings reveal functional heterogeneity and plasticity among naïve CD8 T cells and uncover a mechanism by which high-quality naïve subsets drive robust CD8 T cell responses, providing a previously unrecognized layer of immune regulation. SUMMARY: Our study reveals functional heterogeneity and plasticity within naïve CD8 T cells, identifying high-quality subsets that can emerge from less potent cells and drive superior immune responses through enhanced survival of effector progeny.

  • Open Access

    Mitochondrial metabolic flexibility is critical for CD8 + T cell antitumor immunity

    by Chao Chen, Hong Zheng, Edwin M. Horwitz, Satomi Ando, Koichi Araki, Peng Zhao, Zhiguo Li, Mandy L. Ford, Rafi Ahmed, Cheng-Kui Qu

    Mitochondria use different substrates for energy production and intermediatory metabolism according to the availability of nutrients and oxygen levels. The role of mitochondrial metabolic flexibility for CD8 + T cell immune response is poorly understood. Here, we report that the deletion or pharmacological inhibition of protein tyrosine phosphatase, mitochondrial 1 (PTPMT1) significantly decreased CD8 + effector T cell development and clonal expansion. In addition, PTPMT1 deletion impaired stem-like CD8 + T cell maintenance and accelerated CD8 + T cell exhaustion/dysfunction, leading to aggravated tumor growth. Mechanistically, the loss of PTPMT1 critically altered mitochondrial fuel selection—the utilization of pyruvate, a major mitochondrial substrate derived from glucose—was inhibited, whereas fatty acid utilization was enhanced. Persistent mitochondrial substrate shift and metabolic inflexibility induced oxidative stress, DNA damage, and apoptosis in PTPMT1 knockout cells. Collectively, this study reveals an important role of PTPMT1 in facilitating mitochondrial utilization of carbohydrates and that mitochondrial flexibility in energy source selection is critical for CD8 + T cell antitumor immunity.


  • PD-1 blockade increases the self-renewal of stem-like CD8 T cells to compensate for their accelerated differentiation into effectors

    by Amanda L. Gill, Peter H. Wang, Judong Lee, William H. Hudson, Satomi Ando, Koichi Araki, Yinghong Hu, Andreas Wieland, Sejin Im, Autumn Gavora, et al.

    PD-1 + TCF-1 + stem-like CD8 T cells act as critical resource cells for maintaining T cell immunity in chronic viral infections and cancer. In addition, they provide the proliferative burst of effector CD8 T cells after programmed death protein 1 (PD-1)–directed immunotherapy. However, it is not known whether checkpoint blockade diminishes the number of these stem-like progenitor cells as effector cell differentiation increases. To investigate this, we used the mouse model of chronic lymphocytic choriomeningitis virus (LCMV) infection. Treatment of chronically infected mice with either αPD-1 or αPD-L1 antibody not only increased effector cell differentiation from the virus-specific stem-like CD8 T cells but also increased their proliferation so their numbers were maintained. The increased self-renewal of LCMV-specific stem-like CD8 T cells was mTOR dependent. We used microscopy to understand the division of these progenitor cells and found that after PD-1 blockade, an individual dividing cell could give rise to a differentiated TCF-1 − daughter cell alongside a self-renewing TCF-1 + sister cell. This asymmetric division helped to preserve the number of stem-like cells. Moreover, we found that the PD-1 + TCF-1 + stem-like CD8 T cells retained their transcriptional program and their in vivo functionality in terms of responding to viral infection and to repeat PD-1 blockade. Together, our results demonstrate that PD-1 blockade does not deplete the stem-like population despite increasing effector differentiation. These findings have implications for PD-1–directed immunotherapy in humans.